ICAM1 and Wilson disease: In contrast, an overall improvement in glucose tolerance has been observed in WD-treated mice lacking beta2-integrin function19suggesting that other ICAM-1 ligands may counteract the negative impact of beta2-integrin ligands on glucose metabolism.